The angiogenic regulator CD13/APN is a transcriptional target of Ras signaling pathways in endothelial morphogenesis

Blood

Volumn 101, Issue 5, 2003, Pages 1818-1826

  Bhagwat, Shripad V ^b   Petrovic, Nenad ^b   Okamoto, Yasuhiro ^b   Shapiro, Linda H ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; MICROSOMAL AMINOPEPTIDASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; RAF PROTEIN; RAS PROTEIN;

ANGIOGENESIS; ARTICLE; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE RELEASE; ENDOTHELIUM CELL; ENZYME ACTIVITY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MORPHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

EID: 0037372507     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-05-1422     Document Type: Article

References (70)

1. Folkman J, D'Amore PA. Blood vessel formation: what is its molecular basis? [comment]. Cell. 1996;87:1153-1155.
2. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353-364.
3. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis, Nat Cell Biol. 2000;2:737-744.
4. Eliceiri BP, Cheresh DA. Adhesion events in angiogenesis. Curr Opin Cell Biol. 2001;13:563-568.
5. D'Angelo G, Lee H, Weiner RI. cAMP-dependent protein kinase inhibits the mitogenic action of vascular endothelial growth factor and fibroblast growth factor in capillary endothelial cells by blocking Raf activation. J Cell Biochem. 1997;67:353-366.
6. D'Angelo G, Martini JF, liri T, Fantl WJ, Martial J, Weiner RI. 16K human prolactin inhibits vascular endothelial growth factor-induced activation of Ras in capillary endothelial cells. Mol Endocrinol. 1999;13:692-704.
7. Ilan N, Mahooti S, Madri JA, Distinct signal transduction pathways are utilized during the tube formation and survival phases of in vitro angiogenesis. J Cell Sci, 1998;111:3621-3631.
8. Eliceiri BP, Klemke R, Stromblad S, Cheresh DA. Integrin alphavbeta3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis. J Cell Biol. 1998;140:1255-1263.
9. Larrivee B, Karsan A. Signaling pathways induced by vascular endothelial growth factor (review). Int J Mol Med. 2000;5:447-456.
10. Mechtcheriakova D, Schabbauer G, Lucerna M, et al. Specificity, diversity, and convergence in VEGF and TNF-{alpha} signaling events leading to tissue factor up-regulation via EGR-1 in endothelial cells. FASEB J. 2001;15:230-242.
11. Pasqualini R, Koivunen E, Kain R, et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res. 2000;60:722-727.
12. Bhagwat SV, Lahdenranta J, Giordano R, Arap W, Pasqualini R, Shapiro LH. CD13/APN is activated by angiogenic signals and is essential for capillary tube formation. Blood. 2001;97:652-659.
13. Arbiser JL. American Academy of Dermatology 1997 Awards for Young Investigators in Dermatology: signal transduction and regulation of angiogenesis. J Am Acad Dermatol, 1997;37:772-777.
14. Tamanoi F. Inhibitors of Ras farnesyltransferases. Trends Biochem Sci. 1993;18:349-353.
15. Hara M, Akasaka K, Akinaga S, et al. Identification of Ras farnesyltransferase inhibitors by microbial screening. Proc Natl Acad Sci U S A. 1993;90:2281-2285.
16. Pang L, Sawada T, Decker SJ, Saltiel AR. Inhibition of MAP kinase kinase blocks the differentiation of PC-12 cells induced by nerve growth factor. J Biol Chem. 1995;270:13585-13588.
17. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci U S A. 1995;92:7686-7689,
18. Badger AM, Bradbeer JN, Votta B, Lee JC, Adams JL, Griswold DE, Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function, J Pharmacol Exp Ther. 1996;279:1453-1461.
19. LoGrasso PV, Frantz B, Rolando AM, O'Keefe SJ, Hermes JD, O'Neill EA. Kinetic mechanism for p38 MAP kinase. Biochemistry. 1997;36:10422-10427.
20. Wymann M, Arcaro A. Platelet-derived growth factor-induced phosphatidylinositol 3-kinase activation mediates actin rearrangements in fibroblasts. Biochem J. 1994;298(pt 3):517-520.
21. Arcaro A, Wymann MP. Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses. Biochem J. 1993;296(pt 2):297-301.
22. Yano H, Agatsuma T, Nakanishi S, et al. Biochemical and pharmacological studies with KT7692 and LY294002 on the role of phosphatidylinositol 3-kinase in Fc epsilon RI-mediated signal transduction. Biochem J. 1995;312(pt 1):145-150.
23. Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem. 1994;269:5241-5248.
24. LookAT, Ashmun RA, Shapiro LH, Peiper SC. Human myeloid plasma membrane glycoprotein CD13 (gp150) is identical to aminopeptidase N. J Clin Invest. 1989;83:1299-1306.
25. Shapiro LH, Ashmun RA, Roberts WM, Look AT. Separate promoters control transcription of the human aminopeptidase N gene in myeloid and intestinal epithelial cells. J Biol Chem. 1991;266:11999-12007.
26. Bram RJ, Hung DT, Martin PK, Schreiber SL, Crabtree GR. Identification of the immunophilins capable of mediating inhibition of signal transduction by cyclosporin A and FK506: roles of calcineurin binding and cellular location. Mol Cell Biol. 1993;13:4760-4769.
27. Li X, Lee JW, Graves LM, Earp HS. Angiotensin II stimulates ERK via two pathways in epithelial cells: protein kinase C suppresses a G-protein coupled receptor-EGF receptor transactivation pathway. EMBO J. 1998;17:2574-2583.
28. Miyamoto T, Fox JC. Autocrine signaling through Ras prevents apoptosis in vascular smooth muscle cells in vitro. J Biol Chem. 2000;275:2825-2830.
29. Srivastava SK, Yuasa Y, Reynolds SH, Aaronson SA. Effects of two major activating lesions on the structure and conformation of human ras oncogene products. Proc Natl Acad Sci U S A. 1985;82:38-42.
30. Kerkhoff E, Houben R, Loffler S, Troppmair J, Lee JE, Rapp UR. Regulation of c-myc expression by Ras/Rat signalling. Oncogene. 1998;16:211-216.
31. Flory E, HoffmeyerA, Smola U, Rapp UR, Bruder JT. Rat-1 kinase targets GA-binding protein in transcriptional regulation of the human immunodeficiency virus type 1 promoter. J Virol. 1996;70:2260-2268.
32. Ludwig S, Engel K, Hoffmeyer A, et al. 3pK, a novel mitogen-activated protein (MAP) kinaseactivated protein kinase, is targeted by three MAP kinase pathways. Mol Cell Biol. 1996;16:6687-6697.
33. Mansour SJ, Matten WT, Hermann AS, et al. Transformation of mammalian cells by constitutively active MAP kinase kinase. Science. 1994;265:966-970.
34. Robbins DJ, Zhen E, Owaki H, et al. Regulation and properties of extracellular signal-regulated protein kinases 1 and 2 in vitro. J Biol Chem. 1993;268:5097-5106.
35. Troppmair J, Bruder JT, Munoz H, et al. Mitogen-activated protein kinase/extracellular signal-regulated protein kinase activation by oncogenes, serum, and 12-O-tetradecanoylphorbol-13-acetate requires Rat and is necessary for transformation. J Biol Chem. 1994;269:7030-7035.
36. Hegde SP, Zhao JF, Ashmun RA, Shapiro LH. c-Maf induces monocytic differentiation and apoptosis in myeloid progenitors. Blood. 1999;94:1578-1589.
37. Ashmun RA, Look AT. Metalloprotease activity of CD13/aminopeptidase N on the surface of human myeloid cells. Blood. 1990;75:462-469.
38. Feracci H, Maroux S. Rabbit intestinal aminopeptidase N: purification and molecular properties. Biochim Biophys Acta. 1980;599:448-463.
39. Maroux S, Louvard D, Baratti J. The aminopeptidase from hog intestinal brush border. Biochim Biophys Acta. 1973;321:282-295.
40. Wachsmuth ED, Fritze I, Pfieiderer G. An aminopeptidase occurring in pig kidney, I: an improved method of preparatiom physical and enzymic properties. Biochemistry. 1966;5:169-174.
41. Giancotti FG, Ruoslahti E. Integrin signaling. Science. 1999;285:1028-1032.
42. Thakker GD, Hajjar DP, Muller WA, Rosengart TK. The role of phosphatidylinositol 3-kinase in vascular endothelial growth factor signaling. J Biol Chem. 1999;274:10002-10007.
43. Jiang BH, Zheng JZ, Aoki M, Vogt PK. Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc Natl Acad Sci U S A. 2000;97:1749-1753.
44. Seger R, Ahn NG, Boulton TG, et al. Microtubule-associated protein 2 kinases, ERK1 and ERK2, undergo autophosphorylation on both tyrosine and threonine residues: implications for their mechanism of activation. Proc Natl Acad Sci USA. 1991;88:6142-6146.
45. Boulton TG, Nye SH, Robbins DJ, et al. ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell. 1991;65:663-675.
46. Boutton TG, Yancopoulos GD, Gregory JS, et at. An insulin-stimulated protein kinase similar to yeast kinases involved In cell cycle control. Science. 1990;249:64-67.
47. Bortner DM, Ulivi M, Roussel MF, Ostrowski MC. The carboxy-terminal catalytic domain of the GTPase-activating protein inhibits nuclear signal transduction and morphological transformation mediated by the CSF-1 receptor. Genes Dev. 1991;5:1777-1785.
48. Arbiser JL, Moses MA, Fernandez CA, et al. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc Natl Acad Sci U S A. 1997;94:861-866.
49. Hla T. Lee MJ, Ancellin N, Paik JH, Kluk MJ. Lysophospholipids - receptor revelations. Science. 2001;294:1875-1878.
50. Passaniti A, Taylor RM, Pili R, et al. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Invest. 1992;67:519-528.
51. Hanahan D, Christofori G, Naik P, Arbeit J. Transgenic mouse models of tumour angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models. Eur J Cancer. 1996;32A:2386-2393.
52. Elenbaas B, Spirio L, Koerner F, et al. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev. 2001;15:50-65.
53. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
54. Cross MJ, Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci. 2001;22:201-207.
55. Vinals F, Pouyssegur J. Transforming growth factor beta1 (TGF-beta1) promotes endothelial cell survival during in vitro angiogenesis via an autocrine mechanism implicating TGF-alpha signaling. Mol Cell Biol. 2001;21:7218-7230.
56. Plouet J, Gospodarowicz D. Transforming growth factor beta-1 positively modulates the bioactivity of fibroblast growth factor on corneal endothelial cells. J Cell Physiol. 1989;141:392-399.
57. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med. 1999;5:1359-1364.
58. Ferrara N. VEGF: an update on biological and therapeutic aspects. Curr Opin Biotechnol. 2000;11:617-624.
59. Sjostrom H, Noren O, Olsen J. Structure and function of aminopeptidase N. Adv Exp Med Biol. 2000;477:25-34.
60. Mouritsen S, Meldal M, Werdelin O, Hansen AS, Buus S, MHC molecules protect T cell epitopes against proteolytic destruction. J Immunol. 1992;149:1987-1993.
61. Falk K, Rotzschke O, Stevanovic S, Jung G. Pool sequencing of natural HLA-DR, DQ, and DP ligands reveals detailed peptide motifs, constraints of processing, and general rules. Immunogenetics. 1994;39:230-242.
62. Turner AJ, Hooper HM, Kenny AJ. Metabolism of neuropeptides. In: Kenny AJ, Turner AJ, eds, Mammalian Ectoenzymes. Amsterdam, the Netherlands: Elsevier Scientific Publishing; 1987:211-256.
63. Rawlings ND, Barret AJ. Evolutionary families of peptidases. Biochem J. 1993;290:205-218.
64. Matsas R, Turner AJ, Kenny AJ. Endopeptidase-24.11 and aminopeptidase activity in brain synaptic membranes are jointly responsible for the hydrolysis of cholecystokinin octapeptide (CCK-8). FEBS Lett. 1984;175:124-128.
65. Noble F, Roques BP. Association of aminopeptidase N and endopeptidase 24.15 inhibitors potentiate behavioral effects mediated by nociceptin/orphanin FQ in mice. FEBS Lett. 1997;401:227-229.
66. Konkoy C, Waters S, Davis T. Subchronic haloperidol administration decreases aminopeptidase N activity and [Met5]enkephalin metabolism in rat striatum and cortex. Eur J Pharmacol. 1996;297:47-51.
67. Bausback HH, Ward PE. Degradation of low-molecular-weight opioid peptides by vascular plasma membrane aminopeptidase M. Biochim Biophys Acta. 1986;882:437-444.
68. Hersh LB, Characterization of membrane-bound aminopeptidases from rat brain: identification of the enkephalin-degrading aminopeptidase. J Neurochem. 1985;44:1427-1435.
69. Saiki I, Fujii H, Yoneda J, et al. Role of aminopeptidase N (CD13) in tumor-cell invasion and extracellular matrix degradation. Int J Cancer. 1993;54:137-143.
70. Fujii H, Nakajima M, Saiki I, Yoneda J, Azuma I, Tsuruo T. Human melanoma invasion and metastasis enhancement by high expression of aminopeptidase N/CD13. Clin Exp Metastasis. 1995;13:337-344.